FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Inderjit Singh

Research Profile

Concepts & Ideas

Chemicals & Drugs

Occupations

Chemistry, Pharmaceutical

Procedures

Disorders

Tuberculosis

Co-author Network

Publications

TOP 3
Ramesh Panchagnula; Jitendra Parmar; Kanwaljit Kaur; Inderjit Singh; Shantaram Ramdos Bade; Yasvanth Ashokraj
Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
Ramesh Panchagnula; Jitendra Parmar; J K Kaur; Inderjit Singh; Shantaram R Bhade
Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
Yasvanth Ashokraj; Gunjan Kohli; kanwal jeet kaur; Shantaram R Bhade; Manthena V S Varma; Mahua Sarkar; Namita Kapoor; Inderjit Singh; Sateesh Kandavilli; Ramesh Panchagnula
Feasibility studies on division of fixed dose combinations of anti-tubercular drugs: an improvement in the tuberculosis therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Inderjit Singh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Ramesh Panchagnula; Jitendra Parmar; Kanwaljit Kaur; Inderjit Singh; Shantaram Ramdos Bade; Yasvanth Ashokraj
Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
International journal of pharmaceutics 2006;313(1-2):5-13.
2006: Ramesh Panchagnula; Jitendra Parmar; J K Kaur; Inderjit Singh; Shantaram R Bhade
Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
Methods and findings in experimental and clinical pharmacology 2006;28(3):161-7.
2006: Yasvanth Ashokraj; Gunjan Kohli; kanwal jeet kaur; Shantaram R Bhade; Manthena V S Varma; Mahua Sarkar; Namita Kapoor; Inderjit Singh; Sateesh Kandavilli; Ramesh Panchagnula
Feasibility studies on division of fixed dose combinations of anti-tubercular drugs: an improvement in the tuberculosis therapy.
Journal of clinical pharmacy and therapeutics 2006;31(2):201-3.
2005: Shrutidevi Agrawal; Kanwal Jit Kaur; Inderjit Singh; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2005;9(11):1273-80.
2005: Yasvanth Ashokraj; Inderjit Singh; Kanwal Jit Kaur; Gunjan Kohli; Shantaram R Bhade; Manthena V S Varma; Chaman Lal Kaul; Ramesh Panchagnula
Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2005;9(7):791-6.
2005: Yasvanth Ashokraj; Inderjit Singh; Kanwal Jit Kaur; Gunjan Kohli; Shantaram R Bhade; Manthena V S Varma; Chaman Lal Kaul; Ramesh Panchagnula
Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2005;9(6):697-9.
2005: Shrutidevi Agrawal; Kanwal Jit Kaur; Inderjit Singh; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Determination of rifampicin bioequivalence in a three-drug FDC by WHO and indian protocols: effect of sampling schedule and size.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2005;9(1):75-80.
2004: Yasvanth Ashokraj; Shrutidevi Agrawal; Manthena V S Varma; Inderjit Singh; K Gunjan; Kanwal Jit Kaur; Shantaram R Bhade; Chaman Lal Kaul; J M Caudron; J Pinel; Ramesh Panchagnula
Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2004;8(9):1081-8.
2004: Shrutidevi Agrawal; Inderjit Singh; Kanwal Jit Kaur; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin.
Pharmacological research : the official journal of the Italian Pharmacological Society 2004;50(3):317-27.
2004: Shrutidevi Agrawal; Inderjit Singh; Kanwal Jit Kaur; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
International journal of pharmaceutics 2004;276(1-2):41-9.
2002: Shrutidevi Agrawal; Inderjit Singh; Kanwal Jit Kaur; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
International journal of clinical pharmacology and therapeutics 2002;40(10):474-81.
2002: Shrutidevi Agrawal; Kanwal Jit Kaur; Inderjit Singh; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
International journal of pharmaceutics 2002;233(1-2):169-77.
2001: Anand Babu Dhanikula; Ramesh Panchagnula; Inderjit Singh; Kanwal Jit Kaur; Chaman Lal Kaul; J S Sekhon
Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2.
Methods and findings in experimental and clinical pharmacology 2001;23(2):93-8.
2000: Ramesh Panchagnula; Shrutidevi Agrawal; Kanwal Jit Kaur; Inderjit Singh; Chaman Lal Kaul
Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2000;4(12):1169-72.
2000: Ramesh Panchagnula; Kanwal Jit Kaur; Inderjit Singh; Chaman Lal Kaul
Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
Methods and findings in experimental and clinical pharmacology 2000;22(9):689-94.
1999: Ramesh Panchagnula; Inderjit Singh; Kanwal Jit Kaur; Chaman Lal Kaul
Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
Methods and findings in experimental and clinical pharmacology 1999;21(9):625-8.
1999: Ramesh Panchagnula; Kanwal Jit Kaur; Inderjit Singh; Chaman Lal Kaul
The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1999;3(11 Suppl 3):S336-42; discussion S351-2.